Johnson & Johnson (NYSE:JNJ) Shares Down 1.5%

Johnson & Johnson (NYSE:JNJ) shares were down 1.5% during trading on Tuesday . The company traded as low as $156.44 and last traded at $157.56. Approximately 2,568,313 shares traded hands during mid-day trading, a decline of 65% from the average daily volume of 7,323,391 shares. The stock had previously closed at $159.88.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on JNJ shares. HSBC upgraded Johnson & Johnson from a “hold” rating to a “buy” rating and upped their price objective for the company from $169.00 to $170.00 in a report on Thursday, April 18th. StockNews.com cut Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a report on Thursday, August 8th. Morgan Stanley upped their price objective on Johnson & Johnson from $167.00 to $169.00 and gave the company an “equal weight” rating in a report on Thursday, July 18th. Cantor Fitzgerald restated an “overweight” rating and set a $215.00 price target on shares of Johnson & Johnson in a research note on Monday, August 5th. Finally, TD Cowen decreased their price target on Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating on the stock in a research note on Thursday, July 18th. Seven equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and an average price target of $173.21.

Johnson & Johnson Stock Down 0.9 %

The business has a 50-day moving average price of $151.41 and a two-hundred day moving average price of $153.07. The company has a quick ratio of 0.85, a current ratio of 1.07 and a debt-to-equity ratio of 0.44. The firm has a market cap of $381.19 billion, a PE ratio of 9.81, a price-to-earnings-growth ratio of 2.63 and a beta of 0.52.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, July 17th. The company reported $2.82 earnings per share for the quarter, topping analysts’ consensus estimates of $2.71 by $0.11. Johnson & Johnson had a return on equity of 36.60% and a net margin of 46.34%. The business had revenue of $22.45 billion for the quarter, compared to analyst estimates of $22.33 billion. During the same quarter in the prior year, the company earned $2.80 earnings per share. The company’s revenue was up 4.3% on a year-over-year basis. On average, equities research analysts expect that Johnson & Johnson will post 10.07 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 10th. Investors of record on Tuesday, August 27th will be issued a $1.24 dividend. This represents a $4.96 annualized dividend and a yield of 3.13%. The ex-dividend date of this dividend is Tuesday, August 27th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 30.92%.

Hedge Funds Weigh In On Johnson & Johnson

Several large investors have recently bought and sold shares of the business. Thrivent Financial for Lutherans boosted its stake in Johnson & Johnson by 31.8% in the second quarter. Thrivent Financial for Lutherans now owns 1,634,863 shares of the company’s stock valued at $238,951,000 after acquiring an additional 394,518 shares in the last quarter. Sei Investments Co. boosted its stake in Johnson & Johnson by 10.7% in the second quarter. Sei Investments Co. now owns 1,126,658 shares of the company’s stock valued at $164,672,000 after acquiring an additional 109,205 shares in the last quarter. Pacer Advisors Inc. boosted its stake in shares of Johnson & Johnson by 15.3% during the second quarter. Pacer Advisors Inc. now owns 240,605 shares of the company’s stock worth $35,167,000 after buying an additional 31,908 shares during the period. Skandinaviska Enskilda Banken AB publ boosted its stake in shares of Johnson & Johnson by 3.9% during the second quarter. Skandinaviska Enskilda Banken AB publ now owns 852,641 shares of the company’s stock worth $124,622,000 after buying an additional 31,863 shares during the period. Finally, AE Wealth Management LLC boosted its stake in shares of Johnson & Johnson by 21.7% during the second quarter. AE Wealth Management LLC now owns 321,514 shares of the company’s stock worth $46,992,000 after buying an additional 57,335 shares during the period. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.